Montes de Oca SL, Victorero AA

Language: Spanish
References: 15
Page: 275-283
PDF size: 149.44 Kb.

ABSTRACT

Introduction: Guillain Barre Syndrome is a demyelinating, acute, inflammatory polyneuropathy mediated by immune mechanisms, with much variable results and clinical development, and constitutes the most frequent cause of acute flaccid paralysis generalized in the world.
Objective: to clinically and epidemiologically characterize Gullain Barre patients, and also the electromyographic variants, the application of diagnosis criteria, and further evolution.
Material and method: a descriptive retrospective research was carried out from January 2009 to September 2013. The sample consisted of 12 patients admitted with diagnosis of Guillain Barré.
Results: most of the cases presented in 2009, with a predominance of female patients of ages 50-59 years. The most frequent predisposing factors are the respiratory tracts infections, and the variant of acute demyelinating inflammatory polyneuropathy. Diagnosis criteria were applied on more than 90% of the cases. Most patients were admitted alive with sequels.
Conclusions: the 50% of the patients were included within the age groups 50-59 years, the female sex predominating, as well as the antecedent of respiratory tracts infections, the variant of acute demyelinating inflammatory polyneuropathy was the most frequent, diagnosis criteria were applied in most of the patients, and there was only one death.

REFERENCES

1. Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain- Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology. 2011; 36(2).

2. Anand B. Pithadia K, Nimisha K. Review on Guillain-Barré syndrome. Pharmacological. 2010; 62.

3. Greene SK, Rett M, Weintraub ES, et al. Risk of confirmed Guillain-Barré syndrome following receipt of monovalent inactivated influenza A (H1N1) and seasonal influenza vaccines in the vaccine safety datalink project, 2009-2010. Am J Epidemiol. 2012; 175(11).

4. Sejvar JJ, Pfeifer D, Schonberger LB. Guillain-Barré syndrome following influenza vaccination: causal or coincidental? Curr Infect Dis Rep. 2011; 13(4).

5. Galeotti F, Massari M, D´Alessandro R, Begui E, Chio A, et al. Risk of Guillain- Barré syndrome after 2010-2011 influenza vaccination. Eur J Epidemiol. 2013; 28(5).

6. Raphaël JC, Chevret S, Hughes RAC, Annane D. Plasma exchange for Guillain- Barré syndrome. Cochrane Database of Systematic Reviews. 2012; 7.

7. Kuitwaard K, de Gelder J, Tio-Gillen AP, et al. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome. Ann Neurol. 2009; 66(5).

8. Walgaard C, Lingsma HF, Ruts L, Drenthen J, van Koningsvel R, et al. Prediction of respiratory insufficiency in Guillain-Barré syndrome. Ann Neurol. 2010 Jun; 67(6).

9. Parellada J, Hidalgo AO. Comportamiento de los pacientes con Síndrome de Guillain-Barré grave. Estudio cooperativo en dos Hospitales Clínico-Quirúrgicos. Rev Cub Med Int Emerg. 2002; 1(1).

10. Lestayo Z, Hernández JL. Análisis del comportamiento del síndrome de Guillain- Barré. Consensos y discrepancias. Rev Neurol. 2008; 46(4).

11. Wise ME, Viray M, Sejvar JJ. Guillain-Barré syndrome during the 2009-2010 H1N1 influenza vaccination campaign: population-based surveillance among 45 million Americans. Am J Epidemiol. 2012; 175(11).

12. De Wals P, Deceuninck G, Toth E, Boulianne N, Brunet D, Boucher RM, et al. Risk of Guillain-Barré syndrome following H1N1 influenza vaccination in Quebec. JAMA. 2012; 308(2).

13. Melano E, Carrillo E, Gulías A, Ávila JA. Síndrome de Guillain-Barré en el anciano: un estudio retrospectivo. Arch Neurocien. 2004; 9(2).

14. Tokars JI, Lewis P, DeStefano F, et al. The risk of Guillain-Barré syndrome associated with influenza A (H1N1) 2009 monovalent vaccine and 2009_2010 seasonal influenza vaccines: results from self-controlled analyses. Pharmacoepidemiol Drug Saf. 2012; 21(5).

15. Sejvar JJ, Kohl KS, Gidudu J, Amato A, Bakshi N, Baxter R, et al. Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2011; 29(3).